Katherine Stueland compensation by year
GeneDx Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $453,557 | $675,000 | $675,000 | $715,869 |
| Bonus | $573,800 | $0 | $950,000 | $0 |
| Stock awards | $5,445,707 | $2,829,420 | $2,796,800 | $11,738,600 |
| Option awards | $5,397,727 | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $1,075,500 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $11,563 | $70,915 | $0 | $17,250 |
| Total | $11,882,354 | $3,575,335 | $4,421,800 | $13,547,219 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GeneDx Holdings Corp. DEF 14A filed April 30, 2026, accession 0001818331-26-000030, and prior-year filings. Open the filing on EDGAR.
How this page was built: the GeneDx Holdings Corp. filed document, accession 0001818331-26-000030. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 240,000 | $31,214,400 | — |
| RSU | 93,750 | $12,193,125 | — |
| PSU | 47,684 | $6,201,781 | — |
| RSU | 47,684 | $6,201,781 | — |
| RSU | 26,186 | $3,405,751 | — |
| RSU | 7,748 | $1,007,705 | — |
| Option | 13,452 | — | $72.60 |
Per the Outstanding Equity Awards at Fiscal Year-End table in GeneDx Holdings Corp.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
22 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-16 | Sale | — | 3,039 | $99.00 | 115,476 |
| 2026-09-16 | Exercise or conversion derivative | — | 18,750 | $0.00 | 37,500 |
| 2026-09-16 | Sale | — | 148 | $95.41 | 124,181 |
| 2026-09-16 | Sale | — | 1,648 | $94.26 | 124,329 |
| 2026-09-16 | Sale | — | 4,141 | $98.27 | 118,515 |
| 2026-09-16 | Sale | — | 1,525 | $96.90 | 122,656 |
| 2026-09-16 | Exercise or conversion | — | 18,750 | $0.00 | 125,977 |
| 2026-09-09 | Sale | — | 3,692 | $84.22 | 107,227 |
The 8 most recent of 22 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments GeneDx discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | $1,434,000 | $16,495,951 | $22,188 | $18,669,139 |
| Resignation for good reason, no change in control | $1,434,000 | $976,615 | $22,188 | — |
| Change in control and involuntary termination | $1,434,000 | $16,495,951 | $22,188 | $18,669,139 |
| Involuntary termination without cause | $1,434,000 | $976,615 | $22,188 | — |
Per the Potential Payments Upon Termination or Change in Control table in GeneDx Holdings Corp.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
GeneDx’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Katherine Stueland · this page | Chief Executive Officer | $13,547,219 |
| Kevin Feeley | Chief Financial Officer | $4,688,926 |
| Bryan Dechairo | Chief Operating Officer | $3,582,375 |
Board service
GeneDx board · FY2023–FY2025How this board is paid
Company policy: GeneDx pays directors a $40,000 cash retainer and $200,000 in Options and RSUs. As stated in GeneDx's FY2023 proxy.
The full GeneDx compensation record
free company briefThis page is one person within GeneDx's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the GeneDx proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GeneDx's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GeneDx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order WGS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.